By Fineline Cube 
Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.
DF-006 Mechanism and Potential
DF-006 is an oral alpha-kinase 1 (ALPK1) agonist that effectively activates the innate immunity of the liver. This mechanism of action positions DF-006 as a novel therapeutic approach for patients with HBV and HCC. Preclinical studies have shown that the combination of DF-006 and alpha-interferon enhances the anti-HBV effect, highlighting its potential as a valuable addition to existing treatment regimens.
Clinical Development Progress
The drug has demonstrated positive anti-HBV activity in multi-dose escalation studies. It has completed single-dose and multi-dose escalation studies in healthy subjects, providing a solid foundation for further clinical development. This progress underscores Drug Farm’s commitment to advancing innovative therapies for liver-related diseases.-Fineline Info & Tech